Tech Company Financing Transactions

Avalyn Pharma Funding Round

Eventide Asset Management, Perceptive Xontogeny Venture Fund and SR One Capital Management participated in a $175 million Series C funding round for Avalyn Pharma. The funding round was announced on 9/27/2023.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

701 Pike St. 1500
Seattle, WA 98101
USA

Phone

Undisclosed

Website

www.avalynpharma.com

Email Address

[email protected]

Overview

Avalyn is developing inhaled approaches to treat people with severe respiratory disease. Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Bruce Montgomery

        

Chief Scientific Officer

Mark Surber

        

VP - Finance

Nancy McKinley

        

VP - Operations

Kelly Otto

        

VP - Product Management

Stephen Pham

        

Browse more venture capital transactions:

Prev: 9/26/2023: Adela venture capital transaction
Next: 9/27/2023: Axial Shift venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary